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ABSTRACT  
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Magnetic Iron Oxide Nanoparticles (Fe-NPs) can be exploited in biomedicine as agents for 
Magnetic Fluid Hyperthermia treatments (MFH) and contrast enhancers in Magnetic Resonance 
Imaging (MRI).  New, oleate covered, Iron Oxide particles have been prepared either by 
coprecipitation or thermal decomposition methods and incorporated into PLGA 
(PLGA=Poly(lactic-co-glycolic acid) nanoparticles (PLGA-Fe-NPs) to improve their 
biocompatibility and “in vivo” stability. Moreover, the PLGA-Fe-NPs have been loaded with 
Paclitaxel to pursue an MFH triggered drug release. Remarkably, it has been found that the 
nanoparticles formulations are characterized by peculiar 1H-NMRD profiles that directly correlate 
with their heating potential when exposed to an alternating magnetic field. By prolonging the 
magnetic field exposure to 30min a significant drug release was observed for PLGA-Fe-NPs in the 
case of the larger sized magnetic nanoparticles. Furthermore, the immobilization of lipophilic Fe-
NPs in PLGA-NPs allowed to maintain Néel relaxation as the dominant relaxation contribution 
also in the presence of large iron oxides cores (diameter of 15-20nm) with the advantage of 
preserve their efficiency when they are entrapped in the intracellular environment. The herein 
reported results show that NMRD profiles are a useful tool for anticipating heating capabilities of 
Fe-NPs designed for MFH applications.     
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION  
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Nanoscale stimuli-responsive systems are under intense scrutiny with the aim of providing 
therapeutic treatments characterized by limited unspecific cytotoxic effects. Among different 
physical triggers, large alternating magnetic fields (AMF) enable the conversion of magnetic 
energy into heat by using magnetic nanoparticles that generate localized hyperthermia named 
magneto fluid hyperthermia (MFH)1,2. It has been suggested that this methodology can be 
exploited in cancer therapy either directly or/and for thermally activated drug release. However, 
despite the promising results, iron oxide based MFH has not yet been translated to routine clinical 
practice for the following main reasons: i) the low heating power of the clinically approved iron 
oxide nanoparticles; ii) their limited ability to target tumour cells; iii) their inhomogeneous 
distribution in the tumour tissue. In order to reach the concentration needed for a successful 
treatment, MFH treatments have to rely on the direct injection of magnetic nanoparticles into the 
tumour.  Many efforts are currently devoted to the preparation of more efficient iron oxide particles 
to make MFH a competitive therapy in particular to treat metastasis and spreading tumour 
masses3,4. To date all magnetic nanoparticles used in vivo are composed of magnetite (Fe3O4) and 
maghemite (-Fe2O3) due to their low toxicity and their known biodistribution and metabolism5. 
To prevent agglomeration, particles are coated with protective shells (e.g. polymers like dextran, 
starch, aminosilane, and polyethylene glycol). Different mechanisms are responsible for the 
thermal energy generated by magnetic nanoparticles in the presence of an alternating magnetic 
field. They are related to the magnetic properties of the nanoparticles (i.e. the overall magnetization 
(Ms), and the effective anisotropy constant (Keff) that are strictly dependent on their size, shape, 
coating and chemical composition6,7. Briefly, heat dissipation arises from the delayed response to 
the time dependent applied magnetic field. It depends on the relaxation of the magnetic moment 
that may occur through e-ither the spin fluctuations within the crystal (Néel) or the rotation of the 
particle itself (Brownian)8-10. The optimal frequency of the AC magnetic field that should be used 
to obtain the maximum heat dissipation depends on the size of the magnetic nanoparticle and on 
the viscosity of the medium11-12. 
The effective relaxation time () of the magnetic particles is defined as  
1
𝜏
=
1
𝜏𝑁
+
1
𝜏𝐵
                                                                 (1)                                                              
5 
 
where N and B are the Néel and Brownian magnetic relaxation times, respectively. The shorter 
relaxation time determines the dominant relaxation mechanism. 
Band N magnetic relaxation times of a particle are given by the following equations8: 
𝜏𝐵 =
3𝜂𝑉𝐻
𝑘𝑇
                                                                (2) 
𝜏𝑁𝐴𝑟𝑟 = 𝜏0 𝑒𝑥𝑝
𝐸𝐴.𝐴𝑟𝑟
𝑘𝑇
                                            (3)     
𝜏𝑁,𝑉𝐹 = 𝜏0,𝑉𝐹𝑒𝑥𝑝
𝐸𝐴,𝑉𝐹
𝑘(𝑇−𝑇0)
                                      (4)    
Where isthe viscosity, VH the hydrodynamic particle volume,  k the Boltzmann constant, T the 
temperature, 0 = 10-9 s, EA is the average energy barrier for the reversal of the magnetization and 
T0 is a phenomenological parameter estimated by the Vogel-Fulcher model. 
N is described by the Arrhenius equation (Equation 3) or by the modified heuristic Vogel-Fulcher 
model13 (Equation 4)  in the presence of not-interacting or interacting particles, respectively.         
The relative contribution arising from Néel and Brown relaxation processes depend on the particle 
size, shape and chemical characteristics. The Néel time has an exponential dependence on 
magnetic anisotropy and particle volume, whereas the Brownian correlation time varies linearly 
with particle volume and solvent viscosity14.  Whereas, Néel relaxation is not influenced by 
viscosity of the medium11,15, Brownian relaxation is influenced markedly by this parameter. It 
follows that if the viscosity of the medium is high or the particle reorientational motion is reduced 
as a consequence of particles aggregation or entrapment in intracellular compartments 
(endosomes, lysosomes), the heat dissipated by the Brownian mechanism decreases dramatically8.  
Furthermore, theoretical and experimental results strongly suggest that highly efficient 
intracellular hyperthermia modality can be achieved by exploiting the Néel rather than the 
Brownian relaxation. Thus to improve the efficiency of the MFH treatment, and to establish a 
robust relationship between “in vitro” and “in vivo” experiments it is essential to use particles that 
relax through Néel relaxation. Moreover, it is crucial for the development of MFH to rely on 
analytical methods able to characterize new magnetic nanoparticles and to predict their heating 
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capacity in physiological conditions.  For example, the theory behind the calculation of the 
anisotropy constant from magnetic measurements often neglects interparticle interactions, so that 
the obtained values reported in the literature show often marked discrepancies among studies 
dealing with similar particles16.  
In this study, the MFH properties of newly prepared iron oxide nanoparticles (Fe-NPs) with a 
diameter ranging from about 5 to 18 nm, coated with oleate moieties and prepared either by co-
precipitation or thermal decomposition methods have been evaluated in relation to their size and 
shape. The selected synthetic methods, apart from being two of the most used techniques for the 
production of iron oxide nanoparticles, proved to be easy and reliable routes for the synthesis of 
nanoparticles with both regular (thermal decomposition) and irregular (co-precipitation) shape 
with diameters ranging from 5 to 18 nm. This would allow for the study of their MFH properties 
in relation to their morphology in terms of shape and size distribution. Since the magnetic 
nanoparticles are stabilized toward aggregation by coating with oleate molecules, they are 
completely insoluble in water.  In order to improve Fe-NPs bioavailability they were incorporated 
into PLGA (Poly(lactic-co-glycolic acid) nanoparticles (PLGA-Fe-NPs)17-19. The incorporation of 
magnetic nanoparticles inside PLGA-Fe-NPs has many advantages3,20-23 i) it improves the 
magnetic nanoparticles stability and bioavailability; ii) it allows their efficient dispersion in water; 
iii) it avoids their aggregation; iv) it hampers the Brownian relaxation by blocking magnetic 
nanoparticles inside the PLGA-Fe-NPs solid core thus allowing Néel relaxation, also in the 
presence of  larger particles. The results from the “in vitro” characterization can be immediately 
used for foreseeing the “in vivo” behavior. The correlation between field dependence of the 
longitudinal relaxation rate (R1obs), described by the so-called Nuclear Magnetic Resonance 
Dispersion (NMRD) profile, for different types of nanoparticles and their heating power has been 
investigated. For iron oxide particles the inner sphere contribution to the water protons relaxation 
is negligible whereas the outer sphere term is the dominant one14,24,25. Outer sphere relaxation is 
essentially due to the diffusion of the water protons near the local variable magnetic field generated 
by the paramagnetic ion. Thus, by analyzing the dipolar interaction between proton spins and the 
magnetic moment of the nanocrystal it is possible to extrapolate important information about the 
magnetic nanoparticles namely, their average distance of minimum approach to the metal ion 
(rNMRD in Table 3), their specific magnetization Ms, their anisotropy energy Ea, and their Néel 
relaxation time τN that determine the heating potential of the magnetic nanoparticles. Moreover, 
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PLGA-Fe-NPs have been loaded also with an anticancer hydrophobic drug currently used in the 
treatment of ovarian and breast cancer (Paclitaxel, PTX) in view of developing MFH triggered 
drug release 26,27.  
 
 
2. EXPERIMENTAL SECTION 
2.1 Synthesis of magnetic iron oxide nanoparticles  
Iron(III) acetilacetonate ([Fe(acaca)3]), iron(III) chloride hexahydrate (FeCl3∙6H2O), iron(II) 
chloride tetrahydrate (FeCl2∙4H2O), oleyl amine, oleyc acid, 1,2-tetradecanediol, ammonium 
hydroxide (25% aq. sol.), diphenyl ether, dibenzyl ether, ethanol, n-hexane were purchased by 
Aldrich. All reagents were used as provided by the manufacturer without further purification. The 
nanoparticles of the series C1 and C12 have been synthesised according to a slight modification 
of the method proposed by Sun et al28. A solution of iron(III) acetylacetonate (5 mmol) in diphenyl 
(C1) or dibenzyl (C12) ether (50 ml) has been treated with 1,2-tetradecanediol (25 mmol), 
oleylamine (15 mmol) and oleic acid (15 mmol) at 200°C for 1 h and then at reflux under nitrogen 
atmosphere and vigorous mechanical stirring. After cooling at room temperature and washing with 
ethanol, the nanoparticles have been separated magnetically and dispersed in n-hexane. 
Nanoparticles of the series C5 have been synthesized according to the method proposed by 
Ghasemi et al.29 by coprecipitation from a solution of iron(II) and iron(III) chloride (25 and 50 
mmol respectively) in deionized water (150 ml) with ammonium hydroxide as a base. After adding 
the base under vigorous mechanical stirring until pH reaches 11, oleic acid (5 % vol.) is added to 
the dark suspension and the temperature is raised to 60°C for 30 min.  The black-brown precipitate 
is separated magnetically, washed several times with water and finally dispersed in n-hexane.  
2.2 PLGA-Fe-NPs preparation 
Poly(D,L-lactide-co-glicolide) (PLGA) RG 502H 50:50, average molecular weight (Mw) 30000-
60000Da, and Poly(vinyl alcohol), Mw 31000−50000 Da (98−99% hydrolyzed) was provided by 
Sigma-Aldrich and Paclitaxel was purchased from Aurisco Pharmaceutical Limited ( China). 
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PLGA-Fe-NPs were obtained using an oil-in-water emulsion solvent extraction method. The 
emulsion was prepared dissolving 100 mg of PLGA, 1 mg of Paclitaxel (PTX) and Iron oxide 
nanoparticles (5 mg of Iron) in 2 mL of chloroform; this solution was called phase 1. Phase 2 
consisted of 3% w/v PVA aqueous solution (4 mL). Phase 1 was added into phase 2 drop to drop 
and sonicated for 300sec at 100% of power. The final emulsion was transferred to a 100 ml round-
bottom flask and put into a rotary evaporator (at 740 mmHg and 30 rpm) for 150 min to remove 
the organic solvent. Non-entrapped drug was removed by dialysis (molecular weight cutoff of 14 
000 Da) carried out at 4 °C against an isotonic NaCl/Hepes buffer (HBS). The excess of PVA was 
removed by washing the emulsion with vivaspin filters (Sartorius) (cutoff of 1 × 106 Da) by 
centrifugation at 5000 rpm for 3 times with 20ml of buffer HBS.  
The amount of Fe entrapped in PLGA-Fe-NPs was determined by using inductively coupled 
plasma mass spectrometry (ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample 
digestion was performed with concentrated HNO3 (70%, 1 ml) under microwave heating 
(Milestone MicroSYNTH Microwave labstation). The hydrated mean diameter of PLGA-Fe-NPs 
was determined using a dynamic light scattering (DLS) Malvern Zetasizer 3000HS (Malvern, 
U.K.). All the samples were analysed at 25°C in filtered PBS buffer (cut-off point: 100 nm; pH 7). 
2.3 Determination of Paclitaxel concentration in nanoparticles 
The drug loading efficiency was determined in duplicate by HPLC (Alliance Waters 2695, 
Milford, Massachusetts, USA). The mobile phase consisted in acetonitrile/water (50:50). The 
reverse phase was X-Bridge C18 5μm. The flow rate was set 1.0ml/min and the detection 
wavelength is 227 nm. The HPLC was calibrated with standard solutions of 10 to 150 μg/ml of 
PTX dissolved in acetonitrile (R2 = 0,99984). The limit of quantification was 0.6 ng/ml. The 
samples were freeze-dry and sonicated in ultrasonic bath with chloroform for 30 min. After 
centrifugation at 5000 rpm for 10 min and evaporation of chloroform, they were sonicated again 
with acetonitrile for 15min and then analysed by HPLC. The encapsulation efficiency was defined 
by the ratio of measured and initial amount of PTX encapsulated in nanoparticles.  
2.4 1H/T1 NMRD Profiles  
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The 1/T1 nuclear magnetic relaxation dispersion profiles of water protons were measured over a 
continuum of magnetic field strength from 0.00024 to 0.5 T (corresponding to 0.01–20 MHz 
proton Larmor frequency), on the fast field cycling (Stelar Spinmaster FFC 2000 relaxometer) 
equipped with a resistive low inductance air cored solenoid, made in silver and used in Fast Field 
Cycling NMR relaxometers30. The relaxometer operates under complete computer control with an 
absolute uncertainty in the 1/T1 values of ±1%. The typical field sequences used were the NP 
sequence between 20 and 8 MHz and PP sequence between 8 and 0.01 MHz. The observation field 
was set at 16 MHz. T1 was determined by the saturation recovery method. 16 values of delay () 
between pulses have been used. The number of averaged experiments was 2. Water proton T1 
measurements at fixed frequency were carried out on a Stelar Spin Master Spectrometer [Stelar 
S.n.c., Mede (PV), Italy] operating in the range from 20 to 80 MHz, by means of the inversion 
recovery method (16 delays () values, two averages). The reproducibility of the T1 data was ± 
5%. 
2.5 TEM analysis.  
The Transmission Electron Microscopy (TEM) analysis (TECNAI FEI G2 microscope) has been 
used to analyze the morphology of the nanoparticles highlights both the PLGA-Fe-NPs shell and 
the magnetic nanoparticle content.  
2.6 Heating by means of time-varying magnetic field Studies.   
The device to apply the time-varying magnetic field to magnetic nanoparticles is composed by a 
voltage generator EASYHEAT 8310 LI connected to a cylindrical inductor. The EASYHEAT 
8310 LI supplies the inductor with a voltage up to 700 Vrms in a frequency range between 150 and 
400 kHz. The copper inductor is a cylindrical solenoid with 7 turns, an internal diameter of 8 cm 
and a length of 15 cm. An image of the measurement set-up is in Figure 4. The sample is logged 
in Teflon container where a 5 ml glass vial is screwed to the cup of the container (Figure 4). The 
temperature is measured by means of an Optocom Fotemp-1H thermometer with a TS3/2 fiber 
optic. The fiber optic is inserted in the 5 ml glass vial by means of a hole in the center of the cup. 
The temperature is sampled with a time step of 1 s. 
The inductor supplied by a time varying current of 400 A at 177 kHz is able to generates a magnetic 
field with a pick value close to 18 kA/m (corresponding to a magnetic flux density in air of 22.6 
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mT). The experiments have been carried out for a time 5 min or for 30 min. During each 
experiment the temperature has been acquired as a function of the time.  
2.7 Stability and in vitro drug release 
Paclitaxel loaded nanoparticles, at concentration of 2.3 μg/ml in 2 ml of PBS, were transferred to 
dialysis bags (MWCO: 10000 Da) and placed in 50 mL of PBS with stirring at 110 rpm/37 °C. At 
determined time intervals (6, 24 and 48 hours), the environmental buffer solution was removed 
and replaced with fresh PBS. The removed buffer was freeze-dry and sonicated in ultrasonic bath 
with 10 ml of chloroform for 30 min. After centrifugation at 5000rpm for 10min and evaporation 
of chloroform, they were sonicated again in ultrasonic bath with 0.2 ml of acetonitrile for 15min 
and then analyzed by HPLC, as described above. 
 
3.  RESULTS AND DISCUSSION 
Iron oxide magnetic nanoparticles, used for the preparation of the PLGA nanocomposites, were 
obtained by two synthetic procedures, namely: i) co-precipitation in basic conditions from an 
iron(II/III) chlorides containing solution (sample C5) and ii) thermal decomposition of an 
organometallic derivative of iron(III) in the presence of oleic acid and oleylamine as surfactants 
(samples C1 and C12).  Magnetic nanoparticles size and morphology were obtained by TEM 
analysis (Figure 1). For each samples the average size was evaluated using ImageJ software and 
the average particle sizes are shown in Table 1.  As expected the nanoparticles obtained by co-
precipitation (C5) show a higher dispersity and a larger average diameter compared to the samples 
obtained by thermal decomposition. The presence of a relatively small fraction (about 17%) of 
particles with larger diameter (18.0 ± 1.7 nm) has been taken into account for both NMRD and 
MFH studies. Thermal decomposition can produce very regular spherical nanoparticles at the 
lower boiling temperature of phenyl ether (Figure 1, C1) while, moving to benzyl ether the higher 
reflux temperature led to the formation of irregularly shaped nanoparticles (Figure 1, C12) 
characterized by an increased size and polydispersity. In fact, as shown in Figure 1,  C12 samples 
contains a fraction (13%) of particles with larger diameter (15.6 ± 3.8) and with a not spherical 
shape (triangle, diamond)  that markedly affected the magnetic properties of the sample as 
described below.      
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Table 1. Metal core diameters of Fe-NPs measured by TEM. 
Fe-NPs 
 
Diameter (nm) (TEM) Preparation method 
C1 5.2 ± 0.9 Thermal decomposition 
C5 9.7 ± 2.8 (83%); 18.0 ±1.7(17%) Co-precipitation 
C12 5.1 ± 1.0 (87%); 15.6 ± 3.8 (13%) Thermal decomposition 
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Figure 1. TEM images of the different magnetic nanoparticles with their relative histograms of 
size distribution. 
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3.1 PLGA-Fe-NPs preparation and characterization.  
PLGA-Fe-NPs were obtained by the o/w emulsion solvent extraction method31. The organic phase 
was prepared by dissolving PLGA RG 502H, Fe-NPs, and paclitaxel in chloroform. The water 
phase was a poly(vinyl alcohol) (PVA) aqueous solution. PVA is the most commonly used 
emulsifier for the preparation of PLGA-NPs because it yields particles that are relatively uniform, 
small sized, and easy to be re-dispersed in water32. To obtain PLGA nanoparticles the organic 
phase was added to the aqueous phase, and the resulting mixture was extensively sonicated. The 
nanospheres were prepared by slow organic solvent evaporation of the o/w emulsion. The 
encapsulation yields in PLGA-Fe-NPs are reported in Table 2. The amount of iron in PLGA-Fe-
NPs was determined by ICP-MS whereas paclitaxel concentration was determined by HPLC using 
a reverse phase column33.The differences in % loaded Fe are the consequence of the different 
particles re-dispersion efficiency in the organic solvent. The average hydrodynamic diameters of 
PLGA-Fe-NPs were obtained by dynamic light scattering (DLS) measurements, and they are 
reported in Table 1. The longitudinal (r1) and transverse (r2) millimolar relaxivities (21.5 MHz, 25 
°C) of the PLGA-Fe-NPs are reported in Table 2.  
PLGA-Fe-NPs %Fe %PTX Diameter/DLS 
r1p 
[mM-1s-1] 
r2p 
[mM-1s-1] 
PLGA-C1 96±2 - 121±2 nm 3.7±0.9 175±30 
PLGA-C5 68±9 40±12 164±12 nm 9.5±0.8 393±20 
PLGA-C12 12±7 27 ± 5 159±7 nm 10.6±1.4 300±20 
 
Table 2. PLGA-Fe-NPs composition; diameters (measured by Dynamic Light Scattering); r1p and 
r2p (measured at 21.5 MHz and T=25°C). 
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Figure 2 shows TEM images of the PLGA-Fe-NPs. The average diameter resulted to be about 80-
90 nm whereas the hydrodynamic size measured by DLS was significantly larger (120-170 nm). 
This difference has been explained by the presence of a large solvation shell, typical of PLGA 
based nanoparticles, when dispersed in an aqueous medium34. The occurrence of this shell causes 
an overestimation of the hydrodynamic size.  
Partial aggregation of the magnetic particles inside the PLGA core has been observed for PLGA-
C5 and in minor extent, for PLGA-C12. 
 
Figure 2. TEM images of PLGA-Fe-NPs 
 
3.2 Relaxometric Properties of PLGA-Fe-NPs.  
Figure 3 displays the T1 magnetic field dependence (NMRD) of PLGA-Fe-NPs compared with 
Endorem (a commercially available SPIO particle used as MRI contrast agent).  The shape of the 
curves is typical of the relaxation induced by superparamagnetic particles14, i.e. the loading into 
the PLGA matrix seems not affecting the overall magnetic properties of the iron oxide particles. 
Differences in shapes of NMRD profiles are depending on the particle properties (size, clustering, 
Néel relaxation time and saturation magnetization).  The water proton longitudinal relaxation 
arises from the dipolar interaction between the magnetic moments of water protons and the electron 
magnetic moment of the iron oxide particles and it is modulated by Néel relaxation (flip of the 
particle magnetic moment from different anisotropy directions) and water diffusion. Theories are 
available to describe relaxation for small and large particles24,25. At low magnetic fields, for 
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particles with a diameter > 15 nm, the high crystal anisotropy maintains the particle magnetic 
moment locked onto the anisotropy axis. Since they can flip from one easy direction to another, 
the relaxation can occur through either Néel relaxation or water diffusion. On the contrary, at high 
magnetic fields, the Néel relaxation is not possible since the magnetic moment is locked onto the 
magnetic field direction and the modulation is due to water diffusion (τD ). For very small particles, 
characterized by a smaller anisotropy energy, the locking of the particle magnetization onto the 
anisotropy directions does not occur and Néel relaxation becomes irrelevant also at low magnetic 
fields. In this study, the longitudinal NMRD profiles have been fitted using the Roch's heuristic 
model35 modified by Lascialfari et al13 that has been developed for particle core diameter < 20 nm.  
Fitting equations were written using Matlab software (see supplementary information). For the 
fitting of C5 and C12 samples the TEM radius of larger diameter particles (Table 1) have been 
used.    
 
Figure 3. Profiles of 1/T1 1H-NMRD (25°C and pH=7.4) of PLGA-Fe-NPs loaded with the different 
magnetic nanoparticles: C12 (○), C5 (▲), Endorem (□), and C1 (●). The solid lines between data 
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points are the result of the data analysis (see the equations in supplementary information). PLGA-
Fe-NPs profiles are the average of 4 different preparations. Error bars represent the SD of the 
experimental data. 
 
The relaxation rate at very low fields is directly proportional to the crystal anisotropy energy and 
particle volume. Figure 3 shows dramatic differences (C1<endorem<C5) in low field relaxation 
rates of PLGA loaded with magnetic particles. The observed behaviour reflects differences in 
crystal shape, N and size of magnetic core from TEM images (Figure 2). Tentatively, the 
unexpected profile of PLGA loaded with C12 particles can be explained by the presence of  ca. 
13% of larger particles (15.6 ± 3.8 nm diameter) characterized by a not spherical shape. Apparently 
this fraction represents the dominant contribution to the observed NMRD profile. At high field the 
relaxation rate only depends on τD (translational correlation time) and the inflection point 
corresponds to the condition defined by ωIτD ∼1. Since τD = r2/D, where D is the water diffusion 
coefficient (2.3x10-5 cm2/s) the determination of τD from the NMRD profile allows to estimate the 
distance of minimum approach (rNMRD). Table 3 reports τN , τD,, Ms,  and r obtained by the fitting 
of NMRD profiles for the different PLGA-Fe-NPs and Endorem. The hydrodynamic iron oxide 
core sizes derived from the NMRD profile are larger than those ones obtained by TEM but 
significantly smaller than the hydrodynamic sizes of the whole PLGA-Fe-NPs particles (80-90 and 
120-170 nm by TEM and DLS, respectively).  These effects result from the fitting procedure of 
the NMRD profiles, which depends on the distance of minimum approach of water molecules to 
the metal core whereas TEM data give the real size of the magnetic core. Being the magnetic 
particles embedded in the PLGA framework particles we can conclude that water can relatively 
freely diffuse inside this material and the free diffusion is inversely proportional to the PLGA-NPs 
size30,36. Since the rNMRD  appears independent by the TEM-measured size of the Fe-NPs, one can 
hypothesize than the observed relaxation rates are limited by the hindered water diffusion inside 
the PLGA matrix that it can be assumed to be analogous in the different PLGA-NP preparations. 
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PLGA-Fe-NPs rTEM [nm] rNMRD [nm] τD [ns] MS,NMRD [emu g-1] τN  [s rad-1] 
PLGA-C1 2.6 ± 0.5 15.8 ± 0.8 108 ± 11 108 ± 20 1.69 ± 0.97 x 10-9 
Endorem 2.5 ± 0.5 6.35 ± 0.29 17.5 ± 1.6 98.5 ± 9.6 3.7 ± 1.2 x 10-9 
PLGA-C5 9.0 ± 0.9 13.2 ± 0.3 75.8 ± 3.9 62.1 ± 2.6 2.73 ± 0.48 x 10-7 
PLGA-C12 7.8 ± 1.9 13.9 ± 0.2 84.0 ± 2.6 64.9 ± 2.1 10.95 ± 4.05 x 10-6 
 
Table 3. Best fitting parameters obtained by the analysis of NMRD profiles of PLGA-Fe-NPs 
measured at 25°C. Radius particles have been compared with that obtained by TEM. 
 
From the 1/T1 NMRD profile analysis it is possible to check the reproducibility of nanoparticle 
synthesis and to assess the parameters that influence MFH. On the other hand, from the 
measurement of transverse relaxivity (R2) of PLGA-Fe-NPs suspensions it is possible to evaluate 
their efficiency as T2* agents for MRI applications. In fact, iron oxide nanoparticles can be 
exploited both as contrast agents for MRI in T2* weighted images and as therapeutics in MFH 
making them “ideal” theranostic agents. Table 2 shows that, as expected, highest values of R2 
(measured at 21.5MHz) have been obtained for particles with the largest diameter (PLGA-C5). As 
reported for the 1/T1 NMRD profiles analysis the R2 are not dependent on the size of the whole 
PLGA nanoparticle (ca. 150-180nm) but only on the size of the magnetic core and the distance of 
minimum approach (r). The r2p of PLGA-C5 and PLGA-C12 are particularly high, suggesting their 
use as promising T2* MRI contrast agents.  
 
3.3 Assessment of magnetic hyperthermia properties.  
The PLGA-Fe-NPs were exposed to a time varying magnetic field (Figure 4) in order to evaluate 
their potential in generating magnetic hyperthermia. The temperature increase generated by heat 
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dissipation was recorded as a function of time of exposure to the AMF. The induction device37-38 
(Figure 4) used in this study was developed at the University of Padova and it is described in the 
experimental section. 
 
Figure 4. A photograph of the high-frequency induction device 
 
Typically, heating efficiency of a material is reported in terms of the specific absorption rate (SAR) 
reported in equation (5), where C is the heat capacity of the suspension, msample is the mass of the 
sample, miron  is the mass of iron, and  is the initial slope of the time-dependent heating curve, 
respectively11. 
𝑆𝐴𝑅 = 𝐶 
𝑚𝑠𝑎𝑚𝑝𝑙𝑒
𝑚𝑖𝑟𝑜𝑛
 ∆𝑇
∆𝑡
                                                            (5) 
While the SAR values can have a maximum point at a certain particle size, they are proportional 
to the initial magnetic susceptibility, frequency and strength of the applied field (H0).                                                             
The time dependent temperature curves were fitted by using the phenomenological Box-Lucas 
equation. (Equation 6) 
𝑇(𝑡) = 𝐴(1 − 𝑒−𝐵𝑡)                                                (6) 
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This equation is often used to describe the AMF heating of iron oxide nanoparticles39. The product 
of the fitting parameters, A x B, is equivalent to the initial temperature rise (T/t) and it was used 
to calculate SAR values from equation (5).  
The solutions were placed in an AC magnetic field of frequency ν = 1 77 kHz and amplitude H0 = 
18 kA/m, corresponding to a product H0 ν = 2.4x109 A m-1 s-1 . This value is under the tolerance 
threshold estimated by Hergt and coworkers40 for a small exposed region (H0 ν < 5 x109 A m-1 s-1 
) in order to avoid the production of  tissue heating due to induced eddy currents. Figure 5 shows 
the T measured after a varying magnetic field exposure of 5min. PLGA loaded with C12 and C5 
particles are significantly more efficient than the NPs loaded with smaller C1 ones.  
Figure 5. Temperature increase by magnetic heating of PLGA-Fe-NPs (time exposure 5min). The 
Fe concentration in all solutions was of 20.8 mM (determined by ICP-MS) 
 
The observation is consistent with that reported by Lartigue et al41, particles up to 7 nm do not 
produce significant heating under similar experimental conditions. From these results, one may 
surmise that, in PLGA-C12, the population with larger diameter (ca. 16 nm) represents the species 
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that give the dominant contribution to the observed temperature increase as reported above for the 
observed NMRD profile. Since there is an inverse proportionality between the maximum SAR 
values obtainable with a magnetic nanoparticle and the polydispersity of their size and shape42,43, 
both C5 and C12 synthetic protocol will be improved to reduce the polydispersity of these particles 
and therefore to improve their heating efficiency.  
 Very interestingly, as shown in Figure 6A, there is a direct proportionality between SAR and r1p 
(mM-1 s-1) (as measured at very low magnetic fields, 0.01 MHz).  
 
Figure 6. Plot of SAR values for the PLGA-Fe-NPs as a function of the relaxivity measured at low 
magnetic field (A) and of their size (B). 
At low magnetic fields, the water proton relaxation rate, is directly proportional to the anisotropy 
energy. It follows that the magnetic properties of Fe-NPs embedded in PLGA-NPs are not affected 
by the global motion of the nanoparticle as they dissipate heat through Néel relaxation8-9. This 
observation is confirmed by the bell-shaped behavior of the SAR dependence on magnetic particle 
radius extrapolated by the NMRD profiles (Figure 6B) as theoretically estimated by M. Suto and 
coworkers7.   
3.4 “In vitro” Paclitaxel release triggered by MFH.  
The loading of the PLGA-Fe-NPs with an antitumour drug (Paclitaxel) leads to a “theranostic” 
agent that combines hyperthermia generated cytotoxicity with chemotherapy. This combination 
may allow to reduce the amount of drug and to achieve the synergistic therapeutic effect in treating 
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cancers after a single or few administrations. PLGA has been loaded with paclitaxel and C5 or 
C12 NPs, respectively. Resulting PLGA-Fe-NPs have been exposed to the AMF for 30min. This 
exposure time allowed to reach a maximum external temperature increase of about 12°C for the 
more efficient PLGA-C12 system (Figure 7).  
 
Figure 7. Temperature increase by magnetic heating brought by PLGA-C5 and PLGA-C12 
systems (time exposure 30min). The Fe concentration in the NPs suspensions was of 20.8 mM 
(determined by ICP-MS) 
 
In vitro Paclitaxel release from nanoparticles was estimated in Phosphate Buffer Saline (PBS) at 
6, 24 and 48h after AMF exposure. Paclitaxel loaded nanoparticles (2,3 μg/ml) were diluted in 
PBS (2ml) and transferred to dialysis bags  placed in PBS (50ml) with magnetic stirring at 110 
rpm/37 °C. At appropriate intervals, the buffer solution was replaced with fresh PBS, and the 
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concentration of the released Paclitaxel in the removed PBS was determined by HPLC. Figure 8 
shows the amount of paclitaxel released by PLGA-Fe-NPs after 30min the AMF exposure is 
significantly higher than that measured on both control and on samples exposed to AMF only for 
5min. The heat produced during the MFH treatment is sufficient to destabilize PLGA-Fe-NPs 
triggering their selective drug release. Since C12 and C5 have a high R2/R1 ratio they can be 
exploited as T2
* MRI contrast agents able to report, in real time, their “in vivo” distribution. On 
the basis of the observed contrast enhancement it should be possible to find the most appropriate 
timing to initiate the MFH treatment. 
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Figure 8. Cumulative Paclitaxel release measured at 37°C by HPLC for PLGA-C12 (A) and 
PLGA-C5 (B). 
 
4. CONCLUSION  
The herein reported results have shown that: i) PLGA is a good, biocompatible material to 
encapsulate iron oxide particles to yield stable NPs, easily suspended in aqueous solutions; ii) the 
PLGA-Fe-NPs NMRD profiles allow to predict their performance in both MRI and MFH 
applications; iii) the PLGA matrix does not hamper a free diffusion of water molecules at the 
surface of Fe-NPs; iv) the heating (by MFH) of PLGA-Fe-NPs loaded with Paclitaxel allows a 
triggered release of the drug from the NPs.  Finally, new nanosystems loaded with Fe-NPs and 
Paclitaxel appear very promising systems for designing innovative “theranostic” applications. 
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